On November 9, 2020 Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR bispecific technology platform, reported that it will present two new posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Virtual Annual Meeting, to be held from Monday, November 9, 2020 to Saturday, November 14, 2020 (Press release, Aptevo Therapeutics, NOV 9, 2020, View Source [SID1234570394]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters will provide updates on APVO603, which is wholly owned by Aptevo Therapeutics, and the phase 1-ready ALG.APV-527 developed in partnership with Alligator Bioscience.
The abstracts and the accompanying posters will be available in the Virtual Poster Hall to registered attendees from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020 on the SITC (Free SITC Whitepaper) abstract website. Details will also be posted on the Aptevo Therapeutics website.
Title: APVO603: Dual-targeting of 4-1BB and OX40 with an ADAPTIR bispecific antibody enhances anti-tumor responses to solid tumors
Summary: The data to be presented will highlight preclinical in vivo anti-tumor activity showing that APVO603 significantly reduces tumor burden in a murine bladder cancer model. APVO603 is shown to synergistically enhance CD4, CD8 T-cell and NK cells’ cytotoxic potential when compared to either 4-1BB or OX40 monospecific antibodies alone or in combination. This was demonstrated in multiple in vitro studies showing increased effector cell proliferation, cytokine secretion, granzyme expression and tumor lysis. Lead cell clone has been identified, CMC activities have been initiated and pre-IND studies have begun. Current Preclinical and CMC activities support advancing the APVO603 program towards clinical development for the treatment of multiple solid tumors.
Details of the Oral Presentation:
During Session 208 (Bispecific Antibodies in Cancer Immunotherapy) on Thursday, November 12th at 4 p.m. EST there will be a pre-recorded presentation covering the APVO603 program followed by a live question and answer period.
Details of the Poster Presentation:
Live question and answer sessions will occur for the APVO603 poster (Number 633) on Wednesday, November 11th from 5:15-5:45 p.m. EST and Friday, November 13th from 4:40-5:10 p.m. EST.
Title: ALG.APV-527: Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR bispecific antibody
Summary: The poster will present preclinical data demonstrating that ALG.APV-527 has a favorable safety profile with no indication of systemic immune activation or liver toxicity in NHP or murine models. ALG.APV-527 induces robust in vitro killing of tumors that is dependent on 5T4 engagement. In vivo, ALG.APV-527 augmented anti-tumor responses and promoted tumor-specific memory. Clinical development is planned for ALG.APV-527 and CTA documents are prepared for filing of a phase 1 clinical trial in the European Union for treatment of solid tumors expressing 5T4 such as non-small cell lung cancer, mesothelioma and head and neck cancer.
Details of the Poster Presentation:
Live question and answer sessions will occur for the ALG.APV-527 poster (Number 851) on Wednesday, November 11th from 5:15-5:45 p.m. EST and Friday, November 13th from 4:40-5:10 p.m. EST.